Company Overview

CV Sciences, Inc. (NASDAQ: CVSI) is a U.S.-based consumer wellness company focused on hemp-derived products, nutraceuticals, and cannabinoid-based consumer health solutions. The company primarily operates in the dietary supplements and wellness industries through its flagship consumer brand, PlusCBD Oil, which markets hemp extracts, gummies, softgels, topicals, and other cannabidiol (CBD) products. CV Sciences has also pursued pharmaceutical and drug-development initiatives historically through cannabinoid science and intellectual property development, although its current revenue base is primarily tied to consumer wellness products. Public filings and company disclosures indicate that the company’s core revenue drivers are retail and direct-to-consumer sales of hemp-derived supplements and wellness products.

The company was founded in 2010 and evolved alongside the growth of the U.S. hemp and CBD industry following changes in federal and state cannabis regulations, including the 2018 U.S. Farm Bill. CV Sciences positioned itself as an early entrant emphasizing product quality, compliance standards, and distribution through natural retail channels. The company has focused on differentiating itself through product testing protocols, broad retail distribution relationships, and brand recognition within the hemp-derived wellness category. Available public information indicates that the company has concentrated on maintaining regulatory alignment and expanding product categories as the broader cannabinoid market matured.

Business Operations

CV Sciences conducts operations primarily through its consumer products segment, centered on the PlusCBD Oil brand and related wellness offerings. The company generates revenue through wholesale distribution to natural product retailers, specialty stores, e-commerce platforms, and direct consumer sales. Product categories include tinctures, gummies, capsules, sprays, topicals, and pet-focused wellness formulations. The company has historically emphasized quality assurance, including third-party testing and traceability standards for hemp sourcing and manufacturing. Public disclosures indicate that most operational activity is concentrated within the United States, though certain products have previously reached international markets through distribution arrangements.

The company controls intellectual property related to cannabinoid formulations and wellness applications and has historically explored pharmaceutical development opportunities tied to cannabinoids. CV Sciences has also maintained relationships with manufacturing and supply-chain partners supporting product production and fulfillment. While the company does not operate on the scale of larger multinational consumer health firms, it has established a recognizable niche position in the natural products retail channel. Data from public filings indicate that operations remain relatively concentrated in the hemp-derived wellness sector, with limited diversification outside consumer cannabinoid products.

Strategic Position & Investments

CV Sciences’ strategic direction has focused on expanding consumer wellness offerings while navigating evolving regulatory conditions surrounding CBD and hemp-derived ingredients in the United States. The company has pursued product innovation in functional wellness categories including sleep, calm, immunity, and sports recovery formulations. Publicly available investor materials indicate that management has emphasized retail expansion, operational efficiency, and strengthening brand visibility in natural food and wellness channels. The company has also invested in scientific research and product validation to support consumer confidence and retailer acceptance.

Historically, CV Sciences explored pharmaceutical initiatives involving cannabinoids and drug-development technologies, though current public disclosures suggest a stronger emphasis on consumer packaged wellness products. The company has also pursued acquisitions and strategic product expansions intended to broaden its wellness portfolio and distribution reach. Available public records identify ongoing participation in emerging cannabinoid categories, though regulatory uncertainty surrounding CBD marketing and labeling continues to affect the broader industry. Certain claims regarding future pharmaceutical or international expansion opportunities remain difficult to independently verify beyond company guidance, and some long-term strategic outcomes are therefore inconclusive based on available public sources.

Geographic Footprint

CV Sciences is headquartered in San Diego, California, and its principal market presence is concentrated in the United States. The company distributes products through a network of retailers, natural health stores, and online sales channels across multiple U.S. regions. Public filings and investor materials indicate that the company’s strongest market penetration has historically been within natural products retail and specialty wellness channels rather than mass-market global distribution.

The company has previously referenced international distribution relationships and opportunities in select foreign markets, though publicly verifiable operational scale outside the United States appears limited relative to domestic activities. Its influence internationally is primarily tied to the broader global recognition of hemp-derived wellness products rather than large-scale overseas infrastructure or manufacturing operations. Available public disclosures do not indicate a major multinational operational footprint comparable to larger consumer health companies.

Leadership & Governance

CV Sciences is governed by a board of directors and executive leadership team focused on consumer wellness growth, operational discipline, and regulatory compliance within the hemp-derived products industry. The company’s leadership strategy has emphasized scientific credibility, retail expansion, and navigating changing cannabinoid regulations. Public company disclosures indicate that management has prioritized brand development and operational restructuring during periods of volatility in the CBD sector.

Key executives identified in recent public filings include:

• Joseph Dowling – Chief Executive Officer
• Michael J. Mona, Jr. – President and Chief Operating Officer
• Doyle W. Buehler – Chief Financial Officer
• John R. Fowle – Chairman of the Board

Leadership and governance information is based on publicly available company filings, investor communications, and market disclosures. Certain executive roles and board compositions may change over time, and investors typically verify current appointments through the company’s latest SEC filings and annual reports.